Tevard Biosciences
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
15 Necco St, Boston, Massachusetts, 0221...Website
www.tevard.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Tevard Biosciences
Tevard Biosciences is a biotechnology company focused on developing innovative tRNA-based gene therapies aimed at curing rare genetic diseases, particularly those caused by nonsense mutations. Founded by a team including MIT molecular biologist Professor Harvey Lodish and parents of children with Dravet syndrome, the company seeks to provide durable cures for conditions such as Duchenne muscular dystrophy and dilated cardiomyopathy. Their unique platform allows for broad applicability across various genetic disorders, targeting genes of any size without the risk of overexpression. Tevard's intended clients include patients suffering from rare genetic diseases and their families, as well as the broader medical community seeking effective treatment options.Explore more
Tevard Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tevard Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Tevard Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Tevard Biosciences is spiking on competitors!
Funding: Get notified immidiatlly once Tevard Biosciences has new funding data
Congratulate Masked Content for being promoted to Masked Content at Tevard Biosciences
Click to see if Tevard Biosciences had a recent Job posting/layoffs
Check if Tevard Biosciences has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Tevard Biosciences launches new products
Earning: See what the market has to say on Tevard Biosciences recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Tevard Biosciences as Masked Content
Find more new buyers
Compare Similar Companies to Tevard Biosciences
Compare insights from companies similar to Tevard Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Tevard Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Tevard Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Tevard Biosciences.
Tevard Biosciences Tech Stack
A closer look at the technologies used by Tevard Biosciences
See more technologies
Most Recent Scoops
Facilities Relocation / Expansion
Tevard Biosciences is planning to move offices in December 2024. The move will impact approximately 25 employees at the existing office located at 238 Main St, Cambridge, MA.
Facilities Relocation/Expansion
New Hire
Executive Move
Left Company
Executive Move
Left Company
Executive Move
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Tevard Biosciences
Sign Up For FreeTo access detailed company insights
Tevard Biosciences is a biotechnology company focused on developing innovative tRNA-based gene therapies aimed at curing rare genetic diseases, particularly those caused by nonsense mutations. Founded by a team including MIT molecular biologist Professor Harvey Lodish and parents of children with Dravet syndrome, the company seeks to provide durabl... Read More
